ArticleDiabetes care2025
Plasma Metabolome, Long-term Body Weight Change, and Type 2 Diabetes in U.S. Individuals.
Article in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel amino acid and fatty acid signatures linked to type 2 diabetes risk after gestational diabetes mellitus.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveBody weight influences the blood metabolome, but whether specific plasma metabolomic profiles predict long-term weight change remains unclear. We aimed to investigate associations among plasma metabolites, current weight, weight change trajectories, and incident type 2 diabetes (T2D) in adults. RESEARCH DESIGN AND
methodsWe profiled 260 plasma metabolites in 7,499 U.S. health professionals. A metabolomic score predicting BMI change over time was derived using elastic net regression with a training/testing approach. Associations with incident T2D were examined using multivariable Cox models.
resultsMetabolomic predictors of BMI change varied by baseline weight status. In lean individuals, 46 metabolites significantly predicted BMI change slope compared with 20 individuals in the group with overweight and 13 in the group with obesity, with no overlapping metabolites across groups. A metabolomic score of BMI slope derived in lean participants correlated with BMI slope in the lean group (Spearman r = 0.31), but the correlation was weaker in the groups with overweight (r = 0.16) and obesity (r = 0.10). The score was associated with higher T2D risk in the lean group (hazard ratio [HR] per 1 SD 1.42; 95% CI 1.26-1.60) and group with overweight (HR 1.29; 95% CI 1.17-1.42) but not in the group with obesity.
conclusionsPlasma metabolomic profiles predictive of future weight change differ by body weight status. Distinct metabolic signatures may help identify certain lean individuals at an elevated risk of future weight gain and T2D, offering opportunities for earlier, more targeted prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.